Literature DB >> 30146778

Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.

Amirhossein Bahreyni1,2, Amir Avan3,4, Mohammad Shabani5, Mikhail Ryzhikov6, Hamid Fiuji7, Saman Soleimanpour8, Majid Khazaei3,9, Seyed Mahdi Hassanian3,10,11.   

Abstract

Adenosine and its analogs are of particular interest as potential therapeutic agents for treatment of cardiovascular diseases (CVDs). A2 adenosine receptor subtypes (A2a and A2b) are extensively expressed in cardiovascular system, and modulation of these receptors using A2 adenosine receptor agonists or antagonists regulates heart rate, blood pressure, heart rate variability, and cardiovascular toxicity during both normoxia and hypoxia conditions. Regulation of A2 adenosine receptor signaling via specific and novel pharmacological regulators is a potentially novel therapeutic approach for a better understanding and hence a better management of CVDs. This review summarizes the role of pharmacological A2 adenosine receptor regulators in the pathogenesis of CVDs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  A2 adenosine receptor; cardiovascular diseases; pharmacological inhibitors

Year:  2018        PMID: 30146778     DOI: 10.1002/jcp.27161

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Involvement of β-adrenoceptors in the cardiovascular responses induced by selective adenosine A2A and A2B receptor agonists.

Authors:  Edward S Wragg; Patrizia Pannucci; Stephen J Hill; Jeanette Woolard; Samantha L Cooper
Journal:  Pharmacol Res Perspect       Date:  2022-06

2.  Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways.

Authors:  Alan David Kaye; Syed R Baber; Mohammed T Sharief; Rachel J Kaye; Elyse M Cornett
Journal:  Drugs R D       Date:  2019-12

Review 3.  Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment.

Authors:  Kamila Wala; Wojciech Szlasa; Jolanta Saczko; Julia Rudno-Rudzińska; Julita Kulbacka
Journal:  Biomolecules       Date:  2021-04-24

Review 4.  Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.

Authors:  Rajasekharreddy Pala; V T Anju; Madhu Dyavaiah; Siddhardha Busi; Surya M Nauli
Journal:  Int J Nanomedicine       Date:  2020-05-27

Review 5.  Adenosine Receptor Profiling Reveals an Association between the Presence of Spare Receptors and Cardiovascular Disorders.

Authors:  Emmanuel Fenouillet; Giovanna Mottola; Nathalie Kipson; Franck Paganelli; Régis Guieu; Jean Ruf
Journal:  Int J Mol Sci       Date:  2019-11-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.